Anil Kane

Dr. Anil Kane, Executive Director at Thermo Fisher Scientific, dives into the transformative impact of AI and machine learning in drug development. He explains how predictive modeling is eliminating traditional trial-and-error methods, significantly cutting costs and timelines. Anil shares insights on accelerated stability testing with the ASAP program and the integration of digital tools to enhance manufacturing efficiency. He also discusses the balance between human expertise and AI, and the exciting future of digital transformation in pharmaceuticals.